GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyteir Therapeutics Inc (OTCPK:CYTT) » Definitions » Total Current Liabilities

Cyteir Therapeutics (Cyteir Therapeutics) Total Current Liabilities : $5.97 Mil (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Cyteir Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Cyteir Therapeutics's total current liabilities for the quarter that ended in Sep. 2023 was $5.97

Cyteir Therapeutics Total Current Liabilities Historical Data

The historical data trend for Cyteir Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyteir Therapeutics Total Current Liabilities Chart

Cyteir Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Total Current Liabilities
1.97 3.14 7.51 5.32

Cyteir Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.82 5.32 3.96 6.58 5.97

Cyteir Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Cyteir Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=4.426+0.889
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=5.32

Cyteir Therapeutics's Total Current Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.504+0.016
+Other Current Liabilities+Current Deferred Liabilities
=3.449+0
=5.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Cyteir Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Cyteir Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyteir Therapeutics (Cyteir Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyteir Therapeutics Inc (OTCPK:CYTT) » Definitions » Total Current Liabilities
Comparable Companies
GOSS NYMXF ABOS AADI AAGH CDT GLSI SGMO VOR ACRV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
128 Spring Street, Building A, Suite 510, Lexington, MA, USA, 02421
Website
https://www.cyteir.com
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.
Executives
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joseph S Zakrzewski director 509 WATERVIEW PLACE, NEW HOPE PA 18938
John F Thero director C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Adam M Veness officer: General Counsel C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Stephen H. Sands director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Jeffrey Humphrey director C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Droia Invest Ii Scsp 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Janwillem Naesens director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Sa Ihl 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Karen Hong director 69 PARKSIDE DRIVE, PRINCETON NJ 08540
Bv Wepaven 10 percent owner BRUSSELSESTEENWEG 11, MEISE C9 1860
Luc Verelst 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Df Ii Gp Sarl 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Timothy Romberger director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Racquel Bracken director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421

Cyteir Therapeutics (Cyteir Therapeutics) Headlines

From GuruFocus

Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality

By Business Wire Business Wire • 05-03-2022

Cyteir Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

By Business Wire Business Wire • 11-12-2021

Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

By Business Wire Business Wire • 03-23-2023

Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution

By Business Wire • 06-30-2023

Cyteir Therapeutics to Host Virtual Research and Development (R&D) Day on April 26, 2022

By Business Wire Business Wire • 04-18-2022

Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of Directors

By Business Wire Business Wire • 12-16-2021

Cyteir Therapeutics to Participate in the Credit Suisse 30th Annual Healthcare Conference

By Business Wire Business Wire • 11-01-2021

Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile

By Business Wire Business Wire • 06-03-2023

Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights

By Business Wire Business Wire • 05-10-2023

Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

By Business Wire Business Wire • 08-31-2022